US panel endorses Savient's gout therapy pegloticase
17 June 2009
Sue Sutter
The US
FDA's arthritis advisory committee has overwhelmingly endorsed licensing of
Savient Pharmaceuticals' Krystexxa (pegloticase) for treatment-failure gout, but recommended restricting distribution through a mandatory patient registry and conducting postmarketing studies to monitor for cardiovascular...
Please Login to read the full article.
17 June 2009
Sue Sutter
Please Login to read the full article.
RELATED CONTENT
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
